These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 28235250

  • 1. Brief Report: The Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti-Müllerian Hormone.
    Tamirou F, Husson SN, Gruson D, Debiève F, Lauwerys BR, Houssiau FA.
    Arthritis Rheumatol; 2017 Jun; 69(6):1267-1271. PubMed ID: 28235250
    [Abstract] [Full Text] [Related]

  • 2. Assessment of ovarian reserve by serum anti-Müllerian hormone in patients with systemic lupus erythematosus: a meta-analysis.
    Luo W, Mao P, Zhang L, Chen X, Yang Z.
    Ann Palliat Med; 2020 Mar; 9(2):207-215. PubMed ID: 32156138
    [Abstract] [Full Text] [Related]

  • 3. Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus.
    Mok CC, Chan PT, To CH.
    Arthritis Rheum; 2013 Jan; 65(1):206-10. PubMed ID: 23044647
    [Abstract] [Full Text] [Related]

  • 4. Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve.
    Di Mario C, Petricca L, Gigante MR, Barini A, Barini A, Varriano V, Paglionico A, Cattani P, Ferraccioli G, Tolusso B, Gremese E.
    Endocrine; 2019 Feb; 63(2):369-375. PubMed ID: 30324323
    [Abstract] [Full Text] [Related]

  • 5. [Assessment of ovarian reserve with anti-Müllerian hormone in female patients with systemic lupus erythematosus].
    Chen D, Yuan S, Zhan Z, Zhan Y, Yang X, Liang L.
    Zhonghua Yi Xue Za Zhi; 2014 Apr 08; 94(13):977-80. PubMed ID: 24851682
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients.
    Marder W, McCune WJ, Wang L, Wing JJ, Fisseha S, McConnell DS, Christman GM, Somers EC.
    Gynecol Endocrinol; 2012 Aug 08; 28(8):624-7. PubMed ID: 22296584
    [Abstract] [Full Text] [Related]

  • 8. Assessment of anti-Müllerian hormone levels in premenopausal patients with systemic lupus erythematosus.
    Gasparin AA, Souza L, Siebert M, Xavier RM, Chakr RM, Palominos PE, Brenol JC, Monticielo OA.
    Lupus; 2016 Mar 08; 25(3):227-32. PubMed ID: 26223296
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide.
    Morel N, Bachelot A, Chakhtoura Z, Ghillani-Dalbin P, Amoura Z, Galicier L, Aumaitre O, Piette JC, Pourrat J, Boutin D, Sacre K, Kahn JE, Duhaut P, Farge D, Francès C, Guettrot-Imbert G, Harlé JR, Lambotte O, Le Guern V, Sène D, Trad S, Vidal E, Sarrot-Reynauld F, Gompel A, Tanguy ML, Touraine P, Lacorte JM, Costedoat-Chalumeau N, PLUS group.
    J Clin Endocrinol Metab; 2013 Sep 08; 98(9):3785-92. PubMed ID: 23833039
    [Abstract] [Full Text] [Related]

  • 12. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R.
    Arthritis Rheum; 2002 Aug 08; 46(8):2121-31. PubMed ID: 12209517
    [Abstract] [Full Text] [Related]

  • 13. Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study.
    Sharma SK, Jain S, Bahl P, Potturi P, Rathi M, Naidu S, Sachdeva N, Dhir V, Jain S.
    Arthritis Res Ther; 2020 Aug 14; 22(1):189. PubMed ID: 32799907
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ovarian function is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil.
    Laskari K, Zintzaras E, Tzioufas AG.
    Clin Exp Rheumatol; 2010 Aug 14; 28(1):83-6. PubMed ID: 20346244
    [Abstract] [Full Text] [Related]

  • 16. Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapy.
    Aikawa NE, Sallum AM, Pereira RM, Suzuki L, Viana VS, Bonfá E, Silva CA.
    Clin Exp Rheumatol; 2012 Aug 14; 30(3):445-9. PubMed ID: 22703605
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
    Mok CC, Lau CS, Wong RW.
    Arthritis Rheum; 1998 May 14; 41(5):831-7. PubMed ID: 9588734
    [Abstract] [Full Text] [Related]

  • 19. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
    Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ.
    Arthritis Rheum; 2005 Sep 14; 52(9):2761-7. PubMed ID: 16142702
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.